Foundation Consumer Healthcare (FCH), a maker of popular over-the-counter drugs including Plan B One-Step emergency contraceptive, is leaving the 340B program at the end of this year.
In a Nov. 3 letter to customers, FCH did not say why it is voluntarily exiting the drug pricing program. A company senior executive who signed the letter did not immediately respond to a request for comment.
FCH said it “will no longer be offering 340B pricing for any of its products” effective Dec. 31, and “none of FCH’s products will be included on the PHS price list as of January 1, 2022.”
FCH added that effective Jan. 1 it will discontinue Plan B Clinic Pack (NDC 69536-146-1), a product “offered solely for the clinic market covered by the 340B Drug Pricing Program.”
A spokesperson for the National Family Planning & Reproductive Health Association (NFPRHA) said publicly funded family planning providers should continue to be able to buy generic versions of Plan B (levonorgestrel tablet) at a 340B price.
Over-the-counter drugs distributed pursuant to a prescription are considered covered outpatient drugs for 340B purposes, according to the 340B Prime Vendor Program.
